Description: Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is headquartered in Solna, Sweden.
Home Page: www.promorepharma.com
Fogdevreten 2
Solna,
171 65
Sweden
Phone:
46 8 12 45 48 59
Officers
| Name | Title |
|---|---|
| Dr. Jonas Ekblom Ph.D. | Pres & CEO |
| Mr. Erik Magnusson | Chief Financial Officer |
| Dr. Margit Mahlapuu Ph.D. | Chief Scientific Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3931 |
| Price-to-Sales TTM: | 99.7269 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |